Real‐world evidence of F‐fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System

  • Published on 07/25/2024
  •  Reading time: 4 min.

Nadine A. Friedrich MD 1, Lin Gu MS 2, Justin Waller MS 2, Amanda M. De Hoedt MS 2, Zachary Klaassen MD, MSc 2,3,4, Stephen J. Freedland MD 1,2

1 Division of Urology, Department of Surgery Cedars‐Sinai Medical Center Los Angeles California USA
2 Durham Veterans Affairs Health Care System Durham North Carolina USA
3 Division of Urology, Department of Surgery, Medical College of Georgia Augusta University Augusta Georgia USA
4 Georgia Cancer Center Augusta Georgia USA

Abstract

Background There are no population‐level studies assessing 18F‐fluciclovine (fluciclovine) utilization of Positron emission tomography/computed tomography (PET/CT) for biochemically recurrent prostate cancer (PC). We assessed fluciclovine PET/CT in the Veterans Affairs Health Care System.
Methods Of 1153 men with claims suggesting receipt of fluciclovine PET/CT, we randomly reviewed charts of 300 who indeed underwent fluciclovine...

ContentGeneMD

To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Oncology

Receive our newsletter to stay up to date with the latest news in Oncology